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Abstract. Vitamin D has several important functions including absorption of calcium and phosphorous, and 
facilitating normal immune system function. Sufficient amount of the vitamin is required for normal growth and 
development of bones and teeth, as well as improved resistance against certain diseases. There is growing evidence 
that there are huge benefits of vitamin D in promoting the human health, not only in infants for prevention of rickets 
but also effects on the immune system, blood pressure, reducing the risk of some cancers, prevention of diabetes 
mellitus type 1 trough stimulation of the pancreatic beta cells to secrete insulin.  In contrast to these benefits certain 
patients genetically predisposed are at risk to develop a serious even fatal disease such as idiopathic infantile 
hypercalcemia. Withdrawal of vitamin D and reduction of calcium intake are lifesaving interventions for these babies. 
Recently it was found that recessive mutations in CYP24A1 gene are responsible for this disease. This gene encodes 
the enzyme 24 vitamin D hydroxylase which is important in the degradation metabolic pathway of the vitamin D. 
Although it was generally believed that idiopathic infantile hypercalcemia is the disease limited to infancy a number 
of studies yields that adults may have serious morbidity including nephrolithiasis, nephrocalcinosis, intermittent 
episodes of hypercalcemia leading to chronic kidney disease and in few cases to end stage renal disease. Therefore 
one should be very cautious in liberal prescribing vitamin D supplements and excessive exposure to sunlight, 
particularly in individuals with genetic predisposition. 
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General 

 
Vitamin D is called the “sunshine vitamin” because it’s 
produced in the skin in response to sunlight. Vitamin D 
is a fat-soluble vitamin in a family of compounds that 
includes vitamins D1, D2, and D3. Vitamin D has several 
important functions including absorption of calcium and 
phosphorous, and facilitating normal immune system 
function. Sufficient amount of the vitamin is required for 
normal growth and development of bones and teeth, as 
well as improved resistance against certain diseases. The 
deficiency of vitamin D increases the risk of developing 
bone abnormalities such as osteomalacia or osteoporosis. 
It is believed that a 10 minutes a day of mid-day sun 
exposure is sufficient for production of adequate amount 
of vitamin D. Besides getting vitamin D through sunlight, 
it is provided through intake of certain foods and 
supplements [1]. Certain environmental factors and 
lifestyle influence the ability to get sufficient amounts of 
this vitamin through the sun alone such as pollution, use 
of sunscreen, spending more time indoors, long working 
hours in offices, living in big cities where buildings block 
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sunlight. Therefore it is important to provide additional 
amounts of vitamin D from sources other than sunlight 
exposure. The recommended daily doses of vitamin D 
according to the Institute of Food and Agricultural 
Sciences (IFAS) [2] are: 
 children and teens: 600 IU 
 adults up to age 70: 600 IU 
 adults over age 70: 800 IU 
 pregnant or breastfeeding women: 600 IU 
The consensus of scientific understanding appears to 
be that vitamin D deficiency is reached for serum 25-
hydroxyvitamin D (25OHD) levels less than 20 ng/mL 
(50 nmol/L), insufficiency in the range from 20 
32 ng/mL, and sufficiency in the range from 3380 ng/mL, 
with normal in sunny countries 5490 ng/mL, and excess 
greater than 100 ng/mL. 
Health Benefits 
There is growing evidence that there are huge benefits 
of vitamin D in promoting the human health, not only in 
infants for prevention of rickets but also effects on the 
immune system, blood pressure, prevention of diabetes 
mellitus type 1 trough stimulation of the pancreatic beta 
cells to secrete insulin.  
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Malignancies 
Vitamin D has strong anticancerogenic effect for 
development of malignancies of the breast, colon, prostate, 
ovaries, esophagus, and lymphatic system. Several studies 
have shown that increased dietary intake of vitamin D as 
well as higher blood levels of vitamin D are associated 
with a reduced risk of colorectal cancer [3,4,5,6]. In 
experimental studies it has been found that vitamin D 
prevents the development of cancer trough enhancement of 
cellular differentiation, decreasing cancer cell growth, 
stimulating apoptosis and reducing tumor blood supply and 
angiogenesis [7,8,9,10]. Randomized The Women’s Health 
Initiative study did not confirm the beneficial effect of 
vitamin D supplements for an average period of 7 years in 
reducing the incidence of colorectal cancer [11]. 
The limitation of majority studies which deal with the 
beneficial effects of vitamin D to human health arises from 
the fact that in dietary studies vitamin D produced in the 
skin from sunlight exposure is not taken in consideration. 
In most studies vitamin D level is measured in the blood at 
a single point in time and this may not correspond to a 
person’s true vitamin D status. One may speculate that 
people with higher vitamin D intakes or blood levels have 
healthier behavior in general which reduces the cancer risk. 
Upper respiratory tract infections 
The beneficial effects of the vitamin D were questioned 
in the VIDARIS study reported in JAMA in 2012 [12]. In 
this randomized, double-blind, placebo-controlled trial 
adult participants were randomly assigned to receive an 
initial dose of 200,000 IU oral vitamin D3, then 200,000 
IU 1 month later, then 100,000 IU monthly (n = 161) or 
placebo (n=161) for a total for 18 months,. The endpoints 
of this study were the number of upper respiratory tract 
infection episodes, their severity, duration and days off 
missed work. The results of this study were disappointing; 
no statistical significant difference was found in none of 
tested parameters.  
Hypertension 
In a meta-analysis performed by Kunutsor et al. [13] 
including a total of 283,537 participants, the investigators 
found that for each 10 ng/ml increase in someone’s vitamin 
D levels, there was a 12% lower risk of developing 
hypertension. Also the people with the highest vitamin D 
levels had a 30% lower risk of developing hypertension 
compared to the people with the lowest levels. The 
limitation of this meta-analysis is that the analyzed studies 
were performed in United States and one may wonder if 
these results could be validated in other populations.  
In another American study researchers found that 
that for every increase in vitamin D supplementation 
and vitamin D levels in the body, systolic blood pressure 
decreased but there was no changes in the diastolic blood 
pressure [14].  
The researchers of the Women’s Health Initiative 
Randomized Trial assigned women to either receive 
1,000 mg per day of calcium plus 400 IU per day of 
vitamin D or a placebo pill. The results showed that 
there was no difference in blood pressure changes between 
the groups [15].  
The study from Denmark investigated the effect of 
vitamin D supplements on lowering blood pressure in 
people with hypertension [16]. The study period was 20 
weeks and the subjects were randomized to take 3,000 
IU vitamin D per day D or placebo. This study showed 
that subjects in vitamin D group lowered their blood 
pressure more than those in the placebo group. The 
second conclusion was that subjects in the vitamin D 
group who had low levels of vitamin D at the beginning 
of the study had a bigger reduction in their blood pressures.  
The limitation of abovementioned studies is that the 
hypertensive subjects were taking their medication during 
the study period, so it is uncertain if the lowering of the 
blood pressure was due to vitamin D or prescribed 
antihypertensive therapy.  
Diabetes 
There is evidence from experimental studies that vitamin 
D treatment improves glucose tolerance and insulin 
resistance and that supplementation with vitamin D 
restores insulin secretion in animals [17]. This is an 
indirect effect which is mediated by the flux of calcium 
trough the cell membranes; therefore low levels of 
extracellular calcium diminish insulin secretion. There are 
epidemiological studies which revealed greater incidence 
of type 1 diabetes related to geographic variation. The 
study from Finland analyzed 10,821 children who were 
supplemented with different vitamin D doses [18]. An 
important finding from this study was that children who 
took 2,000 IU of vitamin D daily had 80% lower risk to 
develop type 1 diabetes. Another point from this study was 
that vitamin D supplementation during the first year of life 
was critical for development of type 1 diabetes.  
The evidence supports that maintaining adequate 
vitamin D status during pregnancy, nursing, infancy, and 
childhood may help prevent type 1 diabetes [19]. It is still 
the matter of controversy weather genetics of type 1 
diabetes place individuals at risk for vitamin D deficiency 
or vice versa vitamin D deficiency increases the risk for 
type 1 diabetes. There are no studies to show the 
beneficial effect of vitamin D on the treatment of type 1 
diabetes after diagnosis. Several studies have examined 
the impact of vitamin D supplementation on reversing 
type 1diabetes, and they have not been successful [17].  
Risks 
Cardiovascular risks 
There is evidence that vitamin D deficiency is associated 
with cardiovascular morbidity and mortality, but also 
there is some evidence that high levels of vitamin D may 
also be associated with adverse arterial remodeling and 
poor outcomes [20,21]. It has long been known from case 
series that vitamin D excess can lead to atherosclerosis 
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and vascular calcification in humans. In NHANES III 
study there was a U-shaped relationship between vitamin 
D and mortality risk, particularly in women, with 25(OH)D 
levels >50 ng/L [22]. Although 1 meta-analysis that 
included 8 studies that assessed relatively high 
(>65 nmol/L) levels of 25(OH) found no significant 
change in risk of cardiovascular disease, another meta-
analysis reported evidence of increased mortality with 
25(OH)D concentrations >97.5 nmol/L [23].  
Amer and Qayyum found that excessive vitamin D 
levels above 21 nanograms per milliliter were associated 
with an increase in CRP, which is known inflammatory 
marker and which is associated with the stiffening of blood 
vessels and a greater risk of developing cardiovascular 
problems [24]. 
One may have in mind that the role of vitamin D in 
the prevention and management of cardiovascular 
disease as well as the dose-response relationship of 
potentially harmful effects still remain to be established.  
Idiopathic infantile hypercalcemia 
There is pediatric entity entitled idiopathic infantile 
hypercalcemia (IIH) which presents in infants who may be 
severely ill with vomiting, poor appetite failure to thrive, 
seizures and if unrecognized and inappropriately treated 
may die. Biochemically these babies have hypercalcemia, 
hypercalciuria and suppressed parathormon. Imaging 
studies reveal bilateral nephrocalcinosis (Fig 1). 
Withdrawal of vitamin D and reduction of calcium intake 
are lifesaving interventions for these babies. The etiology 
was unknown until 2001 when Schlingmann and the group 
from Munster reported in The New England Journal of 
Medicine that homozygous CYP24A1 mutations were 
cause for this disease in majority of babies [25]. This 
gene controls the enzyme 24hydroxylase which function 
is to degrade vitamin D and prevent sufficient synthesis 
of calcitriol. The authors wanted to validate their 
findings and therefore tested adult patients from former 
East Germany who had had signs of vitamin D toxicity 
as infants. The practice in East Germany was to 
administer parenterally 2 million units of vitamin D 
during the first 2 years of life. Indeed these adults 
carried homozygous mutations in CYP24A1.  
In Macedonia we have diagnosed on clinical basis 7 
babies with IIH. We tested them for CYP24A1 mutations 
and found that all had typical Central European E143del 
mutation. After the report in The New England Journal of 
Medicine there were additional reports in which CYP24A1 
mutations were found in adult subject with idiopathic 
calcium oxalate nephrolithiasis or unexplained 
nephrocalcinosis [2633]. A study from Israel reported 
a small series of patients with nephrolithiasis/ 
nephrocalcinosis, even some of them progressed to 
terminal renal failure [33]. The etiology has not been 
established for decades and finally all were tested and 
found to carry CYP24A1 mutations. 
Recently in collaboration with Boston Children’s 
Hospital (Harvard Medical School) using targeted next 
generations sequencing we diagnosed IIH in 12 year old 
girl who had incidental nephrocalcinosis [34]. She had 
normal growth and had not any problems as an infant. 
Along with this case and other study reports it is now 
clear that IIH is not the disease exclusively limited to 
infancy. This is important for these patients since they have 
to avoid lifelong vitamin D supplements and sunlight 
exposure. So it s questionable if IIH is a disease limited of 
infancy. The growing number of reports point that adult 
homozygous carriers of CYP24A1 mutations may have 
serious morbidity – calcium oxalate nephrolithiasis, 
nephrocalcinosis, hypercalciuria, intermittent episodes of 
hypercalcemia. In the absence of hypercalcemia 
suppressed PTH may be clue to proper diagnosis. 
Conclusion and Future Directions 
Surely that vitamin D is very attractive for promotion 
overall human health. But one may have in mind that 
liberal administration of vitamin D supplements may 
have adverse effects in genetically susceptible 
individuals. Do we diagnose all patients with IIH? Is 
this only the tip of the iceberg? It seems that only 
patients with severe symptoms come to our medical 
attention. What can we do on the population basis? 
What is the prevalence of CYP24A1 mutations in the 
Balkan populations? These questions remain to be 
answered in the near future. We can easily test for 
E143del. Family relatives will have great benefit of 
such testing. This is also very important for prenatal or 
early postnatal diagnosis of CYP24A1 mutations carriers 
to implement early preventive measures.  
 
Fig. 1 Bilateral medullary nephrocalcinosis in a baby 
with idiopathic infantile hypercalcemia. 
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